Back to search

Article

REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 Results

2021-06-12

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Continued SARS-CoV-2 infections and COVID-19-related hospitalizations highlight the need for effective anti-viral treatments in the outpatient setting. In a descriptive interim analysis of the phase 1/2 portion of a double-blind phase 1/2/3 trial in COVID-19 outpatients conducted between June 16, 2020 and September 4, 2020, REGEN-COV ® (casirivimab plus imdevimab) antibody com...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3f30f2d0-7fb1-5c78-823f-fe07a17f2203
DOI
10.1101/2021.06.09.21257915
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 ResultsDOI 10.1101/2021.06.09.21257915
REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity
Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient settingSemantic proximity
Subcutaneous REGEN-COV Antibody Combination for Covid-19 PreventionSemantic proximity
REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity
Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 OutcomesSemantic proximity
Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1Semantic proximity
The Real-World Effectiveness of an Intranasal Spray A8G6 Antibody Cocktail in the Post-Exposure Prophylaxis of COVID-19Semantic proximity
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19Semantic proximity
Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 OutpatientsSemantic proximity
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variantsSemantic proximity
EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCESemantic proximity
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialSemantic proximity
Select a neighboring publication to make it the new centre.